The Company
Laxxon Medical is a pharma-technology company pioneering cutting-edge 3D screen printing development and manufacturing solutions for the pharmaceutical industry. Laxxon was founded in 2017 by a team of medical and business professionals with 20+ years of experience in the pharmaceutical industry. Our highly skilled team provides comprehensive pharmaceutical services to pharmaceutical partners including R&D, IP, and regulatory services. Laxxon is headquartered in New York City with research and development facilities in Jena, Germany. Together with our partner Evonik, we are developing different additives to optimize the release profile of APIs. We are also in the process of establishing state-of-the-art cGMP 3D screen printing production at Hovione sites in Portugal and New Jersey.
The Technology
Laxxon’s SPID®-Technology (Screen Printing Innovational Drug Technology) is a cutting-edge patented 3D screen printing technology which facilitates different pharmaceutical forms of application such as oral, transdermal, and implantable dosage forms through geometric shaping and heterogeneous distribution of active ingredients. SPID®-Technology is capable of printing small batches for R&D, up to commercial-scale production (up to 1.5MM units per day) without the need to change the manufacturing process.
The Mission
Laxxon is dedicated to revolutionizing the pharmaceutical industry through better, faster and cost-effective solutions which mutually benefit the patient and the industry.
The Solutions
Laxxon’s business model is based upon a three-solution framework:
Laxxon owns the exclusive worldwide rights for the development, production and commercialization of innovative drug delivery systems on the basis of a worldwide patented large-scale 3D screen printing technology (SPID®-Technology).
Board of Directors
About Laxxon Medical
Board of Directors
Edward Kay
Board Member
Edward W. Kay, Jr., age 65, has been a director of the Vuzix Corporation, manufacturer and sale of VR and optical devices since April 2016, and Lead Independent Director since February 2022. Mr. Kay is a Certified Public Accountant who spent his 33-year career with PricewaterhouseCoopers LLP (PwC) working with companies in various industries...
Victoria Boyle-Hebron
Board Member
Victoria Boyle-Hebron, a Pace University graduate, began her career at The Bank of New York and Dow Jones. After years in the investment banking sector, she co-founded and served as a Managing Director for SLGR, a global gold refinery. An accomplished financial and business professional executive, Victoria has over 20 years of industry experience, facilitating...
Scientific Advisory Board
Ulrich S. Schubert
Prof. Dr.
Dr. Schubert is a chemist and professor for Organic and Macromolecular Chemistry at the Friedrich Schiller University Jena. Dr. Schubert studied chemistry at the universities of Frankfurt am Main, Virginia Commonwealth University (Richmond, USA) and Bayreuth, before receiving his doctorate from Bayreuth in a joint PhD thesis...
Ulrich Granzer
Ph. D.
Dr. Granzer graduated as a pharmacist in 1984 from the University of Marburg, followed by Ph.D. studies during which he also acted as lecturer for pharmaceutical chemistry. In 1988 he served in the German Air Force and advanced to the rank of a captain with responsibility for drug safety. In 1989, he started his industry career...
Dr. Van Scoik
Ph. D.
Dr. Van Scoik studied pharmacy before obtaining his doctorate in pharmaceutics at the University of Wisconsin-Madison in 1987. Dr. Van Scoik gained ten years' experience at Abbott Laboratories in the Pharmaceutical Products Division, where his research involved solving problems related to the development of new drugs and new solid...